Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results

David H. Howard, Carolyn Kenline, Hillard M. Lazarus, Charles F. Lemaistre, Richard Maziarz, Philip L. McCarthy, Susan K. Parsons, David Szwajcer, James Douglas Rizzo, Navneet S. Majhail

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective. In 1999, three randomized controlled trials concluded that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/HCT) is no better than conventional chemotherapy for women with breast cancer. This study documents the impact of the trials on use of HDC/HCT and describes how hospitals reacted to the trials. Data Source. We used patient-level data on 15,847 HDC/HCTs reported to the Center for International Blood and Marrow Transplant Research between 1994 and 2005. Study Design. We report trends in total HDC/HCT procedure volume, compare the time to hospitals' exit from the HDC/HCT market between research and nonresearch hospitals, and document trends in hospital-specific volumes in the 2 years before exit. Principal Findings. HDC/HCT volume declined from 3,108 in 1998 to 1,363 the year after trial results were released. In 2002, only 76 procedures were performed. Teaching hospitals and the hospitals that participated in the trials were no slower to discontinue the procedure compared with nonteaching, nonparticipating hospitals. At the hospital level, volume declined steadily in the months before abandonment. Conclusion. The results suggest that comparative effectiveness research studies that report negative results can reduce spending, but specialists may be reluctant to relinquish cutting-edge technologies.

Original languageEnglish (US)
Pages (from-to)1762-1777
Number of pages16
JournalHealth Services Research
Volume46
Issue number6 PART 1
DOIs
StatePublished - Dec 2011

Fingerprint

Breast Neoplasms
Transplants
Drug Therapy
Comparative Effectiveness Research
Information Storage and Retrieval
Hematopoietic Stem Cell Transplantation
Marketing
Teaching Hospitals
Randomized Controlled Trials
Bone Marrow
Technology
Research

Keywords

  • clinical practice patterns/guidelines/resource use/evidence-based practice
  • hospitals
  • Technology adoption/diffusion/use

ASJC Scopus subject areas

  • Health Policy

Cite this

Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results. / Howard, David H.; Kenline, Carolyn; Lazarus, Hillard M.; Lemaistre, Charles F.; Maziarz, Richard; McCarthy, Philip L.; Parsons, Susan K.; Szwajcer, David; Douglas Rizzo, James; Majhail, Navneet S.

In: Health Services Research, Vol. 46, No. 6 PART 1, 12.2011, p. 1762-1777.

Research output: Contribution to journalArticle

Howard, DH, Kenline, C, Lazarus, HM, Lemaistre, CF, Maziarz, R, McCarthy, PL, Parsons, SK, Szwajcer, D, Douglas Rizzo, J & Majhail, NS 2011, 'Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results', Health Services Research, vol. 46, no. 6 PART 1, pp. 1762-1777. https://doi.org/10.1111/j.1475-6773.2011.01296.x
Howard, David H. ; Kenline, Carolyn ; Lazarus, Hillard M. ; Lemaistre, Charles F. ; Maziarz, Richard ; McCarthy, Philip L. ; Parsons, Susan K. ; Szwajcer, David ; Douglas Rizzo, James ; Majhail, Navneet S. / Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results. In: Health Services Research. 2011 ; Vol. 46, No. 6 PART 1. pp. 1762-1777.
@article{b946cf6b620c486bbec82c3c01ef4671,
title = "Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results",
abstract = "Objective. In 1999, three randomized controlled trials concluded that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/HCT) is no better than conventional chemotherapy for women with breast cancer. This study documents the impact of the trials on use of HDC/HCT and describes how hospitals reacted to the trials. Data Source. We used patient-level data on 15,847 HDC/HCTs reported to the Center for International Blood and Marrow Transplant Research between 1994 and 2005. Study Design. We report trends in total HDC/HCT procedure volume, compare the time to hospitals' exit from the HDC/HCT market between research and nonresearch hospitals, and document trends in hospital-specific volumes in the 2 years before exit. Principal Findings. HDC/HCT volume declined from 3,108 in 1998 to 1,363 the year after trial results were released. In 2002, only 76 procedures were performed. Teaching hospitals and the hospitals that participated in the trials were no slower to discontinue the procedure compared with nonteaching, nonparticipating hospitals. At the hospital level, volume declined steadily in the months before abandonment. Conclusion. The results suggest that comparative effectiveness research studies that report negative results can reduce spending, but specialists may be reluctant to relinquish cutting-edge technologies.",
keywords = "clinical practice patterns/guidelines/resource use/evidence-based practice, hospitals, Technology adoption/diffusion/use",
author = "Howard, {David H.} and Carolyn Kenline and Lazarus, {Hillard M.} and Lemaistre, {Charles F.} and Richard Maziarz and McCarthy, {Philip L.} and Parsons, {Susan K.} and David Szwajcer and {Douglas Rizzo}, James and Majhail, {Navneet S.}",
year = "2011",
month = "12",
doi = "10.1111/j.1475-6773.2011.01296.x",
language = "English (US)",
volume = "46",
pages = "1762--1777",
journal = "Health Services Research",
issn = "0017-9124",
publisher = "Wiley-Blackwell",
number = "6 PART 1",

}

TY - JOUR

T1 - Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results

AU - Howard, David H.

AU - Kenline, Carolyn

AU - Lazarus, Hillard M.

AU - Lemaistre, Charles F.

AU - Maziarz, Richard

AU - McCarthy, Philip L.

AU - Parsons, Susan K.

AU - Szwajcer, David

AU - Douglas Rizzo, James

AU - Majhail, Navneet S.

PY - 2011/12

Y1 - 2011/12

N2 - Objective. In 1999, three randomized controlled trials concluded that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/HCT) is no better than conventional chemotherapy for women with breast cancer. This study documents the impact of the trials on use of HDC/HCT and describes how hospitals reacted to the trials. Data Source. We used patient-level data on 15,847 HDC/HCTs reported to the Center for International Blood and Marrow Transplant Research between 1994 and 2005. Study Design. We report trends in total HDC/HCT procedure volume, compare the time to hospitals' exit from the HDC/HCT market between research and nonresearch hospitals, and document trends in hospital-specific volumes in the 2 years before exit. Principal Findings. HDC/HCT volume declined from 3,108 in 1998 to 1,363 the year after trial results were released. In 2002, only 76 procedures were performed. Teaching hospitals and the hospitals that participated in the trials were no slower to discontinue the procedure compared with nonteaching, nonparticipating hospitals. At the hospital level, volume declined steadily in the months before abandonment. Conclusion. The results suggest that comparative effectiveness research studies that report negative results can reduce spending, but specialists may be reluctant to relinquish cutting-edge technologies.

AB - Objective. In 1999, three randomized controlled trials concluded that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/HCT) is no better than conventional chemotherapy for women with breast cancer. This study documents the impact of the trials on use of HDC/HCT and describes how hospitals reacted to the trials. Data Source. We used patient-level data on 15,847 HDC/HCTs reported to the Center for International Blood and Marrow Transplant Research between 1994 and 2005. Study Design. We report trends in total HDC/HCT procedure volume, compare the time to hospitals' exit from the HDC/HCT market between research and nonresearch hospitals, and document trends in hospital-specific volumes in the 2 years before exit. Principal Findings. HDC/HCT volume declined from 3,108 in 1998 to 1,363 the year after trial results were released. In 2002, only 76 procedures were performed. Teaching hospitals and the hospitals that participated in the trials were no slower to discontinue the procedure compared with nonteaching, nonparticipating hospitals. At the hospital level, volume declined steadily in the months before abandonment. Conclusion. The results suggest that comparative effectiveness research studies that report negative results can reduce spending, but specialists may be reluctant to relinquish cutting-edge technologies.

KW - clinical practice patterns/guidelines/resource use/evidence-based practice

KW - hospitals

KW - Technology adoption/diffusion/use

UR - http://www.scopus.com/inward/record.url?scp=81755184338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81755184338&partnerID=8YFLogxK

U2 - 10.1111/j.1475-6773.2011.01296.x

DO - 10.1111/j.1475-6773.2011.01296.x

M3 - Article

VL - 46

SP - 1762

EP - 1777

JO - Health Services Research

JF - Health Services Research

SN - 0017-9124

IS - 6 PART 1

ER -